Antibodies News and Research

RSS

Laureate enters agreement with AVEO to produce AV-203 monoclonal antibody against ErbB3

Laureate Pharma, Inc., a full-service contract development and manufacturing organization, announced today that they have entered into a development and manufacturing agreement to produce AV-203, AVEO Pharmaceutical's (Cambridge, MA) novel monoclonal antibody targeted against ErbB3.

28 Oct 2010

New findings suggest way to treat lung diseases

A new study of an exotic, infectious virus that has caused three recent outbreaks in the United States reveals clues to how the virus might damage lungs during infection. The findings also suggest possible new ways to treat lung diseases in humans.

28 Oct 2010

GTC 2010 third fiscal quarter net loss decreases to $4.5 million from $26.2 million

GTC Biotherapeutics, Inc. today reported its financial results for the third fiscal quarter ended September 30, 2010.

28 Oct 2010

Elan 2010 third quarter total revenue decreases 2% to $281.4 million

Elan Corporation, plc today reported its third quarter and first nine months 2010 financial results.

27 Oct 2010

Study finds association between KRAS p.G13D mutations and cetuximab treatment in colorectal cancer

Even though the cancer-treatment agent cetuximab is not considered effective treatment for KRAS (a gene)-mutated metastatic colorectal tumors, new research indicates that patients with colorectal cancer not responding to chemotherapy and a certain variation of this gene who were treated with cetuximab had longer overall and progression-free survival than patients with other KRAS-mutations, according to a study in the October 27 issue of JAMA.

27 Oct 2010

Biogen 2010 third quarter revenue increase 5% to $1.2 billion

Biogen Idec Inc. a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its third quarter 2010 results.

26 Oct 2010

Lumiphore signs global cooperation with Algeta to integrate Lumi4 complexes

Lumiphore Inc., a portfolio company of Nanostart AG, has signed a global cooperation with Algeta ASA a leading company specializing in innovative radiopharmaceutical therapies to treat cancer patients. The agreement enables the integration of Lumiphore's Lumi4 complexes into the targeted radiotherapeutics and companion diagnostics from Algeta.

From Thermo Fisher Scientific Inc. 26 Oct 2010

aTyr Pharma announces $23 million Series C equity financing

aTyr Pharma, the physiocrine therapeutics company, today announced a $23 million Series C equity financing led by Domain Associates. Domain joins existing venture investors Alta Partners, Cardinal Partners and Polaris Ventures, who also participated in the financing.

26 Oct 2010

Cancer researcher to receive 2010 AACR Award of excellence

John D. Groopman, Ph.D., has been selected to receive the 2010 American Association for Cancer Research-Prevent Cancer Foundation Award for Excellence in Cancer Prevention Research

26 Oct 2010

NIH awards Phase I SBIR grant to develop Generic Antibodies for cancer

Rockland Immunochemicals Inc., a biotechnology company focusing on antibodies and antibody based tools for basic research, diagnostic assay development and preclinical studies, today announced that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health to develop Generic Antibodies "Biosimilars" for the Treatment of Cancer.

26 Oct 2010

New report highlights numerous monoclonal antibodies for treating digestive system cancers

Since the early development of monoclonal antibodies (mAbs), almost forty years ago, twenty-four therapeutic mAbs have been approved, four of them targeting digestive system cancers. Due to this success (two blockbusters reaching sales of over $1 billion), many industrials position themselves on this very attractive sector.

25 Oct 2010

Intercell's IC43 Phase II trial against Pseudomonas aeruginosa infections meets primary endpoint

Intercell AG today announced results from a Phase II clinical trial involving the company's investigational nosocomial vaccine candidate (IC43) against infections with the bacterium Pseudomonas aeruginosa, a leading cause of hospital-acquired infections with increasing antibiotic resistance and hence a very high unmet medical need.

25 Oct 2010

NIH awards three new SBIR grants to Taiga

Taiga Biotechnologies, Inc. today announced that the company has received three new Small Business Innovation Research (SBIR) grants from the National Institutes of Health, totaling $1.7 million. This adds to the two previous grants awarded to Taiga for various applications of its proprietary technology platforms, for a total in NIH funding to date of over $2.1 million.

22 Oct 2010

Biogen, Genentech announce new structure of anti-CD20 collaboration

Biogen Idec and Genentech, Inc. a wholly owned member of the Roche Group today announced that they have agreed to amend their collaboration on antibodies targeting CD20.

22 Oct 2010

Dicerna secures $4 million in second closing of Series B equity financing

Dicerna Pharmaceuticals, Inc. a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology and Dicer Substrate siRNA (DsiRNA) molecules, today announced a second closing of its Series B equity financing, securing an additional $4 million and bringing the total capital raised in this round to $29 million.

22 Oct 2010

Tel Aviv University research links obsessive-compulsive disorder to common childhood illness

A common infection in children, strep throat can lead to problems with a child's heart, joints or brain if left untreated. And when the brain is involved, motor and mental functioning may be compromised, leading to syndromes such as attention deficit disorder and obsessive-compulsive disorder (OCD).

21 Oct 2010

Researchers identify common link among malignant tumor types in all grades of cancer

Researchers from Mount Sinai School of Medicine, in collaboration with investigators of the National Institute of Health and Medical Research (INSERM) of France led by Nicolae Ghinea, PhD, have found a common link among several malignant tumor types in all grades of cancer. This breakthrough may ultimately provide a new diagnostic or therapeutic target to detect cancer early or stop tumor growth.

21 Oct 2010

A universal cancer treatment for a universal cancer marker

A latest study shows that a hormone receptor normally confined to the reproductive organs is found in malignant tumors in many parts of the body. Researchers from the Mt. Sinai School of Medicine in New York City explained that this may mean a new target for the early diagnosis and treatment of cancer. The study was published in the latest issue of The New England Journal of Medicine.

20 Oct 2010

European Commission grants Ipsen's OBI-1 orphan drug status for treatment of hemophilia

Ipsen announced today that the European Commission has granted orphan drug status for OBI-1 for the treatment of hemophilia. Expected to enter pivotal clinical trials before the end of this year, OBI-1 is designed to treat individuals with hemophilia who have developed inhibitory antibodies (inhibitors) against human Factor VIII (hFVIII).

20 Oct 2010

SHIP and PTEN enzymes act cooperatively to suppress B cell lymphoma: Study

Lymphoma is a cancer of the immune system. White blood cells divide again and again, spreading abnormally throughout the body. Lymphomas can arise from two types of white blood cells, T cells or B cells, which divide uncontrollably when the molecular mechanisms that keep them in check go awry.

20 Oct 2010

Antibodies News and Research

Laureate enters agreement with AVEO to produce AV-203 monoclonal antibody against ErbB3

New findings suggest way to treat lung diseases

GTC 2010 third fiscal quarter net loss decreases to $4.5 million from $26.2 million

Elan 2010 third quarter total revenue decreases 2% to $281.4 million

Study finds association between KRAS p.G13D mutations and cetuximab treatment in colorectal cancer

Biogen 2010 third quarter revenue increase 5% to $1.2 billion

Lumiphore signs global cooperation with Algeta to integrate Lumi4 complexes

aTyr Pharma announces $23 million Series C equity financing

Cancer researcher to receive 2010 AACR Award of excellence

NIH awards Phase I SBIR grant to develop Generic Antibodies for cancer

New report highlights numerous monoclonal antibodies for treating digestive system cancers

Intercell's IC43 Phase II trial against Pseudomonas aeruginosa infections meets primary endpoint

NIH awards three new SBIR grants to Taiga

Biogen, Genentech announce new structure of anti-CD20 collaboration

Dicerna secures $4 million in second closing of Series B equity financing

Tel Aviv University research links obsessive-compulsive disorder to common childhood illness

Researchers identify common link among malignant tumor types in all grades of cancer

A universal cancer treatment for a universal cancer marker

European Commission grants Ipsen's OBI-1 orphan drug status for treatment of hemophilia

SHIP and PTEN enzymes act cooperatively to suppress B cell lymphoma: Study

From IHC to multiplexing: A practical guide for modern tissue analysis eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo